Gene regulation Biological function Hua et al., 2018, Cell 174, 564- 
In Brief
Transcription factor binding site remodeling by a risk allele for aggressive prostate cancer results in conversion of a promoter to an enhancer with downstream consequences on long noncoding RNA isoform expression and oncogenesis. The prostate cancer (PCa) risk-associated SNP rs11672691 is positively associated with aggressive disease at diagnosis. We showed that rs11672691 maps to the promoter of a short isoform of long noncoding RNA PCAT19 (PCAT19-short), which is in the third intron of the long isoform (PCAT19-long). The risk variant is associated with decreased and increased levels of PCAT19-short and PCAT19-long, respectively. Mechanistically, the risk SNP region is bifunctional with both promoter and enhancer activity. The risk variants of rs11672691 and its LD SNP rs887391 decrease binding of transcription factors NKX3.1 and YY1 to the promoter of PCAT19-short, resulting in weaker promoter but stronger enhancer activity that subsequently activates PCAT19-long. PCAT19-long interacts with HNRNPAB to activate a subset of cell-cycle genes associated with PCa progression, thereby promoting PCa tumor growth and metastasis. Taken together, these findings reveal a risk SNP-mediated promoter-enhancer switching mechanism underlying both initiation and progression of aggressive PCa.
INTRODUCTION
Prostate cancer (PCa) is a highly heritable disease with a strong genetic component. Early twin studies have suggested that genetic factors contribute to $40% of the risks of developing PCa, which is among the highest in all cancer types (Lichtenstein et al., 2000) . More recently, genome-wide association studies (GWAS) have discovered over one hundred single nucleotide polymorphisms (SNPs) associated with an increased risk of developing PCa (Eeles et al., 2013; Hazelett et al., 2014) . Expansion of these risk SNPs through imputation analyses to include additional linkage disequilibrium (LD) SNPs has collectively explained $33% of familial risks for PCa (Al Olama et al., 2014) . Functional understanding of these risk SNPs has provided new opportunities to elucidate the mechanisms of PCa tumorigenesis (Guo et al., 2016; Huang et al., 2014; Iyer et al., 2015; Whitington et al., 2016; Zhang et al., 2014) . Clinical management of PCa is confounded by over-treatment of indolent disease and a major research focus is on identifying aggressive tumors that are potentially lethal. Interestingly, a few risk SNPs have been previously associated with aggressive disease, including rs35148638 and rs78943174 at chromosomes 5q14.3 and 3q26.31, respectively (Berndt et al., 2015) . In addition, rs11672691 was identified to be associated with both non-aggressive and aggressive PCa in a GWAS meta-analysis (Amin Al Olama et al., 2013) . Furthermore, in a recent study of PCa risk SNPs, rs11672691 was found to be associated with an increased risk for PCa-specific mortality, while the risk alleles of seven other established risk SNPs were inversely associated (Shui et al., 2014) . Clearly, these SNPs can provide genetic insight into the origins of aggressive PCa. However, to date there are no known mechanisms underlying their function.
To fill this gap, we explored the role of rs11672691 in PCa development and progression. We demonstrate that the risk variant at rs11672691 is associated with poor prognosis after diagnosis. Furthermore, we report that rs11672691 and its LD SNP, rs887391, modulate the reciprocal expression of long noncoding RNA (lncRNA) PCAT19 gene isoforms through a promoter-to-enhancer switching mechanism. In particular, the risk allele-activated PCAT19-long isoform promotes PCa tumor growth and metastasis through interaction with the HNRNPAB ribonucleoprotein complex.
RESULTS
rs11672691 Is Associated with PCa Progression and Reciprocal Expression of PCAT19 Gene Isoforms rs11672691, a PCa risk SNP, has been associated with the diagnosis of aggressive and fatal PCa (Amin Al Olama et al., 2013; Shui et al., 2014) . To further understand the role of rs11672691 in PCa progression, we examined the biochemical recurrencefree survival of 127 patients with intermediate risk PCa based on the rs11672691 genotype in the CPC-GENE cohort (Fraser et al., 2017) ( Figure 1A) . Consistent with previous studies, pa- tients with homozygous risk allele genotype G showed significantly shorter biochemical recurrence-free survival compared to patients with the non-risk allele genotype A (p = 0.032), suggesting a role for the risk SNP in disease progression after local therapy.
To delineate the functional locus of rs11672691, we examined its location and performed expression quantitative trait loci (eQTL) analysis. rs11672691 is located within the intronic region of a previously uncharacterized lncRNA, PCAT19, on chromosome 19. Cis-eQTL analysis using 471 normal primary prostate tissue samples (Larson et al., 2015) showed the strongest association between rs11672691 and PCAT19 among all genes in a one mega-base pair window ( Figure 1B ). Detailed annotation of this locus using a comprehensive lncRNA catalog (Iyer et al., 2015) revealed multiple PCAT19 isoforms (Figure S1A) . Of these, two gene isoforms with distinct transcription start sites (TSSs) were most abundant in prostate tumors (Figures S1B and S1C) , and are henceforth referred to as PCAT19-short and PCAT19-long ( Figure 1C ). The TSSs of these two isoforms were confirmed by 5 0 -rapid amplification of cDNA ends (5 0 -RACE) followed by Sanger sequencing (Figures 1C and S1D) .
To assess if these two PCAT19 isoforms were similarly affected by the risk allele, we again performed eQTL analysis using the same normal primary prostate tissue cohort (Larson et al., 2015) . Interestingly, while the risk allele of rs11672691 is significantly associated with decreased abundance of PCAT19-short (false discovery rate [FDR] = 1.45 3 10 À6 ), it is also associated with increased abundance of PCAT19-long (FDR = 1.09 3 10 À21 ) ( Figure 1D ). This finding was replicated in the TCGA prostate adenocarcinoma (PRAD) cohort using the imputed genotype of rs11672691 and expression data from both normal prostate tissues and primary PCa tumor tissues ( Figures 1E, S1E , and S1F). These data suggest that rs11672691 regulates the two PCAT19 isoforms in a reciprocal manner. Consistent with the eQTL data, we observed a trend for reciprocal expression of the two isoforms in TCGA prostate tumor samples ( Figure S1G ). Further supporting divergent functional roles for the two isoforms, PCAT19-short and PCAT19-long showed reciprocal trends in their association with patient disease-free survival in the TCGA cohort (Figures S2A and S2B) , and a high ratio of PCAT19-long/PCAT19-short expression was significantly associated with elevated risk of relapse ( Figure S2C ; p = 0.014). In addition, while the non-risk allele A of rs11672691 is associated with lower risk of relapse, the PCAT19-long/PCAT19-short ratio was able to further stratify patients with elevated risk of relapse within this genotype group (Figures S2D and S2E ; p = 0.0042). Taken together, rs11672691 appears to contribute to PCa progression by reciprocally modulating the abundance of two PCAT19 isoforms.
Transcription Factors NKX3.1 and YY1 Preferentially Bind to Non-risk Alleles at the PCAT19-Short Promoter Region Having demonstrated that rs11672691 is associated with PCa progression and reciprocal expression of PCAT19 isoforms, we next sought to elucidate the underlying mechanisms. rs11672691 is located 142 bp upstream of the PCAT19-short TSS, which is in the third intron of PCAT19-long (Figure 2A ). To characterize the regulatory potential of this SNP region, we examined DNase I hypersensitive (DHS) signals and performed formaldehyde assisted isolation of regulatory elements (FAIRE) analysis, which indicated an open chromatin region in 22Rv1 and LNCaP cells ( Figures S3A and S3B ). Additional chromatin immunoprecipitation followed by sequencing (ChIP-seq) data of RNA polymerase II (PolII) further suggests that rs11672691 is located in the promoter of PCAT19-short ( Figure 2A) . Notably, rs887391, a SNP in LD with rs11672691 (r 2 = 0.87, Figure S1E ), is also located in the same PolII binding site as rs11672691 (Figure 2A ). SNPs in regulatory regions can function by modulating transcription factor binding. Motif analysis showed that rs11672691 overlaps with the binding motif of tumor suppressor NKX3.1. Notably, NKX3.1 has a lower preference for the risk allele ' 'G'' (Figure 2B, left) . Similarly, rs887391 overlaps with a predicted YY1 binding motif, and YY1 has a lower preference for the risk allele ''T'' (Figure 2C, left) . Using 22Rv1 cells heterozygous for both risk SNPs, these predictions were validated through NKX3.1 and YY1 ChIP followed by quantitative PCR (ChIP-qPCR) and Sanger sequencing of the PCR amplicons (Figures 2B and 2C, middle and right) .
Risk Alleles Facilitate Promoter-to-Enhancer Switching to Modulate the Expression of Isoforms Next, to determine how NKX3.1 and YY1 affect expression of PCAT19 isoforms, we conducted small interfering RNA (siRNA)-mediated knockdown of these two factors in LNCaP cells. LNCaP is homozygous for the non-risk alleles of rs11672691 and rs887391, which NKX3.1 and YY1 preferentially bind to, respectively. The knockdown of either NKX3.1 or YY1 resulted in a significant decrease in expression of PCAT19-short ( Figure 3A) , which is consistent with our eQTL analyses and motif predictions ( Figures 1D, 1E , 2B, and 2C). Interestingly, this knockdown also resulted in a significant increase in PCAT19-long expression ( Figure 3A) . These data (B) and (C) . *p % 0.05; **p % 0.01; ***p % 0.001. See also Figure S3 .
suggest that rs11672691 and rs887391 regulate PCAT19-short expression by modulating the binding of transcriptional activators NKX3.1 and YY1 to its promoter. However, how these SNPs also regulate PCAT19-long expression remains elusive.
To explore this, we performed CRISPR-interference (CRISPRi) and CRISPR-activation (CRISPRa) assays with sgRNAs targeting the SNP region, which resulted in a significant decrease and increase of PCAT19-long expression, respectively (Figures 3B and 3C) . As a control, sgRNAs targeting the PCAT19-long promoter region did not affect PCAT19-short expression in both assays ( Figure S3C ). These data suggest that the regulation of PCAT19-long expression by the risk SNP region is not simply through transcriptional interference, in which CRISPRmediated activation of the PCAT19-short promoter should have resulted in decreased, rather than increased expression of PCAT19-long. Interestingly, it was noted in the Roadmap Epigenomics data (Kundaje et al., 2015) that this SNP region displays histone marks associated with both promoter and enhancer in a subset of tissue types ( Figure S3D ). This observation was further supported by H3K4me3 and H3K4me1 ChIP data in 22Rv1 cells ( Figures  3D and S3E) . Therefore, we hypothesized that this risk SNP region can function as both a promoter and an enhancer, and the switching of regulatory phenotypes depends on the risk SNP genotypes.
To validate our hypothesis, we first performed luciferasebased promoter and enhancer assays by cloning the SNP region into two different luciferase reporter vectors. Specifically, we cloned either the non-risk allele or the risk allele fragment to probe for promoter or enhancer activity ( Figure S3F ). From both reporter assays, we observed strong luciferase activity compared to the empty vector control ( Figures 3E and 3F ), supporting our hypothesis of a bifunctional regulatory element. In addition, the non-risk allele fragment showed significantly higher promoter activity ( Figure 3E ), while the risk allele fragment showed significantly higher enhancer activity ( Figure 3F ), suggesting that the switching of promoter and enhancer function is, at least in part, genotype-dependent.
To investigate whether the SNP region is an enhancer for PCAT19-long, we examined the correlation of DHS signals between this region and the PCAT19-long promoter across multiple tissue types using intercellular functional correlation (see STAR Methods). We observed a strong correlation between the DHS signals from these two regions ( Figure S3G ; (C) , (E) , and (F) . *p % 0.05; **p % 0.01; ***p % 0.001. See also Figure S3 . PCC = 0.88), which is significantly higher compared to that expected by chance alone ( Figure S3H ; p < 2.2 3 10
À16
). This correlation predicts a potential promoter-enhancer interaction between these two regions.
To confirm this interaction, we performed chromosome conformation capture (3C) assay in 22Rv1 cells using PstI enzyme digestion. When anchored at the PCAT19-long promoter, the risk SNP region showed a stronger interaction with the PCAT19-long promoter than any of the 19 other neighboring PstI sites tested ( Figure 3G ). Conversely, when anchored at the risk SNP region, the PCAT19-long promoter showed the strongest interaction with the SNP region ( Figure S3I ). This interaction is enriched for the risk allele of rs11672691 ( Figure 3H ), further supporting a role for the risk SNPs in the modulation of regulatory phenotypes. Altogether, we demonstrated that the risk SNP region is a bifunctional regulatory element with both promoter and enhancer activity. While the non-risk allele favors stronger promoter activity to drive PCAT19-short expression, the risk allele favors stronger enhancer activity that promotes PCAT19-long expression through an enhancer-promoter interaction.
PCAT19-Long Promotes PCa Progression PCAT19-short and PCAT19-long have reciprocal expression and clinical relevance, and because PCAT19-long is positively associated with PCa progression, we focused our functional analysis on this gene isoform. Among the PCa cell lines tested, the LNCaP-derived castration resistant model V16A had the highest endogenous PCAT19-long expression ( Figure S4A ). Knockdown of PCAT19-long using siRNA, antisense oligonucleotide (ASO), and small hairpin RNA (shRNA) significantly reduced cell growth in V16A cells . Although LNCaP and 22Rv1 have relatively lower endogenous expression, knockdown of PCAT19-long also reduced cell proliferation of these cell lines ( Figures S4B, S4C , S4F, and S4G). Conversely, overexpression of PCAT19-long increased cell proliferation ( Figures S4H and S4I) .
To determine the role of PCAT19-long in PCa progression, we plated V16A cells in Boyden chambers and measured cell migration and invasion after siRNA-, ASO-, and shRNA-mediated knockdown of PCAT19-long for 24 hr. We consistently observed a significant reduction in cell migration and invasion through the chambers ( Figures 4B and S5A-S5D ). In parallel, we measured cell migration through scratch-wound assay, finding that siRNA-mediated knockdown of PCAT19-long decreased the migration potential of V16A cells, as measured by the fraction of remaining wound area (Figures 4C and S5E) .
To validate our findings in vivo, we injected V16A and 22Rv1 cells stably transduced with shRNAs targeting PCAT19-long or a non-targeting control into NOD/SCID mice. Consistent with our in vitro findings, we observed a significant reduction in tumor growth, weight, and importantly, distant metastases in PCAT19-long knockdown mice compared to control mice ( Figures 4D-4F and S5F). Taken together, our in vitro and in vivo data demonstrate that PCAT19-long drives PCa progression.
PCAT19-Long
Activates a Subset of Cell-Cycle Genes Associated with PCa Progression To further investigate the mechanism by which PCAT19-long promotes PCa progression, we performed RNA sequencing (RNA-seq) in V16A cells treated with either negative control siRNAs or siRNAs targeting PCAT19-long. Two biological replicates were included in each group and high correlations were observed between the replicates ( Figure S6A ; r = 0.995 for siCtrl and r = 0.923 for siPCAT19-long). We then performed differential gene expression analysis, and identified 113 and 16 genes significantly upregulated and downregulated by PCAT19-long, respectively ( Figure 5A ). Gene ontology (GO) analysis identified several cell-cycle-related terms highly enriched in PCAT19-long upregulated genes ( Figure 5B ), in concordance with the function of PCAT19-long in promoting PCa cell proliferation and tumor growth.
To further explore the role of PCAT19-long target genes in aggressive PCa, we first evaluated the clinical significance of the 113 PCAT19-long upregulated genes in the TCGA cohort. We observed that patients with high expression of these genes are significantly associated with shorter disease-free survival ( Figure S6B ; p = 0.0007). We then further devised a representative PCAT19-long activity score based on a panel of 30 genes associated with ''Cell Cycle,'' the top GO category enriched in the 113 genes ( Figure 5B ), and evaluated their clinical significance in three independent PCa cohorts (Figures 5C and S6C; Table S1 ). This score is significantly higher in primary PCa tu- 
Figure 5. (E) and plasmid overexpression (F) of PCAT19-long (n = 2). Data are represented as mean ± SEM, and p values were calculated using Student's t test in (E) and (F) . *p % 0.05; **p % 0.01; ***p % 0.001. See also Figure S6 and Table S1 .
mors compared to benign prostate tissues from the TCGA dataset ( Figure 5C , left; p = 1.0 3 10
À6
). Intriguingly, the score is also significantly higher in patient samples with higher Gleason scores (Figure S6C , left; p = 5.2 3 10 À13 ), suggesting an association with PCa aggression. In addition, the score is highest in patients with metastatic tumors in two additional cohorts (Figures 5C, right, and S6C, right; p = 5.4 3 10 À5 and p < 2.0 3 10 À16 , respectively). These findings support the importance of these PCAT19-long target genes in PCa progression. Furthermore, the high expression group is associated with an elevated risk of disease relapse in the TCGA cohort ( Figure 5D ; p < 0.0001). Finally, representative genes from this gene panel were further validated through real-time qPCR after siRNAand ASO-mediated knockdown, plasmid overexpression and CRISPR-mediated activation of PCAT19-long. Expectedly, we observed decreased and increased expression of these genes from knockdown and overexpression experiments, respectively (Figures 5E, 5F, S6D, and S6E). Our data thus indicate that PCAT19-long drives the progression of PCa through the upregulation of a subset of cell-cycle genes.
PCAT19-Long Interacts with HNRNPAB
To explore how PCAT19-long regulates its target genes, we first determined its cellular localization through cell fractionation followed by real-time qPCR in LNCaP and V16A cells. Similar to most lncRNAs with regulatory potential, PCAT19-long was highly enriched in the nuclear fraction ( Figure S7A ). Nuclear lncRNAs can regulate target gene expression through a variety of mechanisms, commonly involving interaction with protein complexes (Rinn and Chang, 2012) . Therefore, the identification of interacting proteins of PCAT19-long is crucial for understanding its regulatory mechanism.
For this purpose, we adopted a native RNA pull-down method using biotinylated DNA probes against PCAT19-long (Table S2 ; see STAR Methods). This approach retrieved $8% of endogenous PCAT19-long RNA ( Figure S7B ). Silver staining of the pull-down protein complexes identified two unique protein bands at $37 kDa compared to the control pull-down ( Figure 6A ). Mass spectrometry analysis identified the upper band as HNRNPD and the lower band as HNRNPAB. To verify these results, we performed chromatin isolation by RNA pull-down (ChIRP) assay, achieving PCAT19-long pull-down efficiency of up to 47% ( Figures S7C and S7D ). Mass spectrometry analysis of the pull-down proteins identified HNRNPAB but not HNRNPD (Table S3) . We then validated this interaction by western blotting for HNRNPAB after PCAT19-long RNA pull-down ( Figure 6B ). In addition, immunoprecipitation of HNRNPAB followed by realtime qPCR analysis identified strong enrichment of PCAT19-long RNA compared to negative control RNAs, thus confirming the interaction with PCAT19-long ( Figure 6C ).
To understand the role of HNRNPAB in PCa aggression, we monitored cell growth after siRNA-mediated knockdown of HNRNPAB in the V16A cell line. As with PCAT19-long knockdown, decreased HNRNPAB expression also led to a significant decrease in cell proliferation (Figures 6D and S7E) . Clinically, HNRNPAB expression is also elevated in PCa primary tumor samples ( , respectively). To further explore the function of the interaction between HNRNPAB and PCAT19-long, we examined the regulatory effects of HNRNPAB on the expression of PCAT19-long target genes in V16A cells. After siRNA-mediated knockdown of HNRNPAB, we observed significant downregulation of PCAT19-long target genes ( Figure 6F ). In addition, we performed RNA-seq in HNRNPAB knockdown samples, and gene set enrichment analysis (GSEA) showed significant enrichment for the 113 PCAT19-long upregulated genes (FDR = 0.00152) (Figure S7G) . These data support our model on the convergence of HNRNPAB and PCAT19-long pathways in upregulating downstream cell-cycle genes that ultimately promote PCa development and progression.
Taken together, our data suggest a model where the rs11672691 and rs887391 risk alleles alter NKX3.1 and YY1 binding profiles, thereby elevating the abundance of PCAT19-long through promoter-enhancer switching. This then leads to increased formation of the HNRNPAB-PCAT19-long complex, ultimately resulting in subsequent 11.5 p = 6.8e-06
** *** ** ** ** *** *** *** *** *** *** *** *** *** ** ** See also Figure S7 and Table S3 .
upregulation of cell-cycle genes that promote prostate cancer aggression ( Figure 7 ).
DISCUSSION

GWAS have collectively identified over one hundred PCa risk
SNPs, a small number of which are associated with PCa aggressiveness or progression (Amin Al Olama et al., 2013; Pomerantz et al., 2011; Shui et al., 2014; Xu et al., 2010) . Despite the need to better understand PCa progression, the functional mechanisms of these risk SNPs remain largely elusive. Here, we demonstrated the functional mechanisms of rs11672691 in PCa progression through the upregulation of a lncRNA isoform, PCAT19-long. Traditionally, regulatory elements are classified as either promoters or enhancers depending on their genomic locations, associated histone marks and regulatory effects. However, our genomes are highly complex, and here we show a case of a bifunctional regulatory element that can function as both a promoter and an enhancer, creating specificity for lncRNA PCAT19 isoform expression. The identification of bifunctional regulatory elements adds another layer of complexity to gene and isoform regulation. Although intragenic enhancers acting as promoters in alternative tissues have been reported previously (Kowalczyk et al., 2012) , the pervasiveness of bifunctional regulatory elements within the same tissue was not investigated until recently (Dao et al., 2017) , with the mechanisms underlying the bifunctionality remaining largely unknown. We find in this study that risk SNP genotypes can modulate the switching of regulatory phenotypes and reciprocal expression of PCAT19 isoforms. A possible alternative mechanism for the reciprocal expression is that the transcription of PCAT19-short blocks the transcription of PCAT19-long. This model is unlikely based on our CRISPRa data that the activation of the SNP region increases The PCa risk-associated variants at rs11672691 and rs887391 decrease NKX3.1 and YY1 binding to the promoter region of PCAT19-short, altering this region to an enhancer for PCAT19-long. PCAT19-long interacts with HNRNPAB and activates cell-cycle genes that are important for PCa progression. ''X'' denotes unknown transcription factor binding to the enhancer element. ''Y'' and ''Z'' denote other unknown factors in HNRNPAB-PCAT19 complexes.
the expression of PCAT19-long. It is worth noting that although the non-risk allele favors promoter activity and the risk allele favors enhancer activity, both alleles are bifunctional, suggesting that other factors such as local chromatin structure and abundance/occupancy of transcription factors may also play a role in the modulation of bifunctionality and should be considered in future studies. The functional importance of these regulatory elements in normal and cancer biology is not well understood. In this study, we explored the functional relevance of a bifunctional regulatory element at the PCAT19 locus in PCa. This SNP-modulated regulatory element controls the reciprocal expression of two PCAT19 isoforms with different clinical significance. While we mainly focused on the functional mechanisms of the oncogenic PCAT19-long, the potentially tumor suppressive role of PCAT19-short is also worth further investigation. Moreover, while the PCAT19 locus is the strongest candidate region from cis-eQTL analysis, other loci, such as CEACAM21 and CEA-CAM5 that have significant albeit weaker cis-eQTL with rs11672691, may also be regulated by this bifunctional regulatory element, and may contribute to its functional role in promoting aggressive disease. Indeed, an independent study has found that the rs11672691 region functions as an enhancer for CEACAM21 in promoting PCa aggressiveness (Gao et al., 2018 [ 
this issue of Cell]).
Intriguingly, our results indicate that NKX3.1 and YY1 bind at rs11672691 and rs887391, respectively, to promote PCAT19-short expression. Lower binding affinity of both factors was observed at the risk alleles. Consistently, NKX3.1 is a well-known transcription factor that is frequently lost in PCa, particularly through deletion (Asatiani et al., 2005; Cancer Genome Atlas Research Network, 2015) . Loss of NKX3.1 is important for early PCa development, with loss of a single allele sufficient to cause a predisposition to PCa (Abdulkadir et al., 2002; Bhatia-Gaur et al., 1999) . The role of NKX3.1 in PCa progression has also been suggested but is less well understood (Bowen et al., 2000) . Here, we show the loss of NKX3.1 binding at the PCAT19 locus as a possible alternative NKX3.1 loss of function mechanism affecting PCa predisposition and progression. YY1 is a transcription factor that can function in opposing manners, either as a transcriptional activator or a repressor, and can also behave as both a tumor suppressor and an oncogene, in a tumor-type-specific manner (Kashyap and Bonavida, 2014) . Here, we reported an oncogenic loss-of-function of YY1 at the PCAT19 locus through its decreased binding to the PCAT19-short promoter. While previous studies have reported the regulation of a single transcription factor at a given risk locus (Guo et al., 2016; Huang et al., 2014) , here, we demonstrated that two different transcription factors can converge at a single SNP locus to regulate the expression of a lncRNA. Furthermore, while we find that NKX3.1 and YY1 preferentially bind to the non-risk alleles of rs11672691 and rs887391, an independent study reported that HOXA2 preferentially binds to the risk allele of rs11672691 (Gao et al., 2018) . It is therefore possible that the synergy of multiple transcription factors binding facilitate the promoter-enhancer switching.
Upregulation of the cell-cycle pathway is an important feature of PCa progression into the aggressive castration resistant PCa (CRPC) (Wang et al., 2009; Xu et al., 2012) . Hence, there are active research efforts looking into utilizing cell-cycle genes as biomarkers and therapeutic targets (Comstock et al., 2013; Cooperberg et al., 2013; Crawford et al., 2014; Stice et al., 2017) . In our cell line analysis, we identified cell cycle as the top GO category enriched in genes upregulated by PCAT19-long. Based on this category, we derived a PCAT19-long activity score, which is highest in patients with metastatic CRPC and is correlated with poor disease-free survival. Mechanistically, we demonstrated the involvement of HNRNPAB as an interacting protein for PCAT19-long. While HNRNPAB has been reported as an epithelial-mesenchymal transition (EMT) driver in hepatocellular carcinoma (Zhou et al., 2014) , its function in PCa remains elusive. Here, we suggest a novel function of HNRNPAB in cellcycle gene regulation through the PCAT19-long-axis.
While the function of most lncRNAs identified to date remains elusive, their biomarker potential has been studied extensively in recent years, partly due to their tissue-and cancer-specific expression patterns. Increased expression of lncRNAs PCA3, SChLAP1, PCAT1, PCAT18, and MALAT1 have been shown to be associated with PCa development and progression (Guo et al., 2016; Crea et al., 2014; de Kok et al., 2002; Prensner et al., 2011 Prensner et al., , 2014 Ren et al., 2013) . Aside from lncRNAs, GWAS have identified many risk SNPs that contribute to the risk of developing PCa (Eeles et al., 2013; Hazelett et al., 2014) . While the functional mechanisms of most risk SNPs remain unknown to date, many studies have explored the biomarker potential of risk SNPs in PCa (Jiang et al., 2013; Sun et al., 2011; Xu et al., 2009) . In this study, we characterized the mechanisms underlying the regulation of lncRNA PCAT19 by PCa risk SNP rs11672691, and evaluated their association with disease progression. While the risk SNP genotype and lncRNA expression are associated with disease-free survival individually, their combination provided additional value in patient stratification. Therefore, future studies of combining genetic and transcriptomic data in biomarker discovery should be warranted.
In conclusion, we elucidated the functional mechanism of PCa risk SNPs rs11672691 and rs887391 in PCa progression (Figure 7) . At the regulatory level, we reported a risk SNP-modulated promoter-to-enhancer switching mechanism in upregulating lncRNA PCAT19-long. At the functional level, PCAT19-long interacts with HNRNPAB to upregulate a subset of cell-cycle genes, ultimately contributing to PCa cell growth and progression. We propose that similar studies should be undertaken to understand the functional mechanisms of noncoding risk SNPs in cancer. Importantly, involvement of cancer risk SNPs in bifunctional regulatory elements should also be investigated further at a genome-wide level.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: , et al. (2015) . Two susceptibility loci identified for prostate cancer aggressiveness. Nat. Commun. 6, 6889.
Bhatia-Gaur, R., Donjacour, A.A., Sciavolino, P.J., Kim, M., Desai, N., Young, P., Norton, C.R., Gridley, T., Cardiff, R.D., Cunha, G.R., et al. (1999) . Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 13, 966-977.
Bishop, J.L., Thaper, D., Vahid, S., Davies, A., Ketola, K., Kuruma, H., Jama, R., Nip, K.M., Angeles, A., Johnson, F., et al. (2017) . The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer. Cancer Discov. 7, 54-71.
Bowen, C., Bubendorf, L., Voeller, H.J., Slack, R., Willi, N., Sauter, G., Gasser, T.C., Koivisto, P., Lack, E.E., Kononen, J., et al. (2000) . Loss of NKX3. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Mesirov, J.P. (2005) . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550. Sun, J., Kader, A.K., Hsu, F.C., Kim, S.T., Zhu, Y., Turner, A.R., Jin, T., Zhang, Z., Adolfsson, J., Wiklund, F., et al. (2011) . Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer. Prostate 71, 421-430.
Taylor, B.S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B.S., Arora, V.K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) . Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22. 
STAR+METHODS KEY RESOURCES TABLE
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Housheng Hansen He (hansenhe@uhnresearch.ca).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
LNCaP, 22Rv1 and RWPE-1 cell lines were obtained from the American Type Culture Collection (ATCC; CRL-1740, CRL-2404, CRL-11609), 293FT cell line was obtained from ThermoFisher (R70007), and LNCaP-derived V16A cell lines were established by the Zoubeidi lab (Bishop et al., 2017) . LNCaP, 22Rv1 and V16A cells were cultured as recommended in complete RPMI1640 medium (RPMI1640 with 10% FBS (080150, Wisent) and 1% Penicillin and Streptomycin (450-201-EL, Wisent)). RWPE-1 cells were cultured in Keratinocyte serum-free medium (17005042, ThermoFisher) supplemented with Bovine Pituitary Extract and Epidermal Growth Factor 1-53 provided from the same kit. 293FT cells were cultured in complete DMEM medium (DMEM with 10% FBS (080150, Wisent), L-glutamine (25030-081, ThermoFisher) and non-essential amino acids (11140-050, ThermoFisher) supplemented with 50mg/mL Geneticin (4727894001, Sigma-Aldrich). All cells were cultured at 37 C in 5% CO 2 . All cell lines were authenticated by STR every 6 months, and tested for mycoplasma contamination using the MycoAlert Mycoplasma Detection Kit (LT07-118, Lonza). All prostate cell lines are of male Homo sapiens origin.
Animal models
Male NOD/SCID mice between 4-6 weeks of age were bred and obtained from Princess Margaret Cancer Centre Animal Research Centre (PMCC ARC). Mice were housed under pathogen-free conditions in groups of 5, and kept under standard temperature, humidity, and timed lighting conditions mandated by the committee. Ten mice per experimental arm were randomly assigned and used for xenograft experiments. All animal experiments were performed non-blinded and in accordance with the University Health Network and Animal Care Committee.
METHOD DETAILS
Transient knockdown and plasmid overexpression siRNA transfection Control siRNA and siRNAs targeting NKX3.1, YY1 and HNRNPAB were purchased from ThermoFisher. Control siRNA and siRNAs targeting unique exons of the PCAT19-long isoform were purchased from GE Dharmacon. siRNA target sequences or catalog numbers are listed in Table S2 . Lipofectamine RNAiMax reagent (13778150, ThermoFisher) was used to transfect siRNAs according to manufacturer's instructions. Briefly, 3 3 10 5 cells were plated in 6-well plates overnight and incubated the next day with the transfection mixture (9 mL Lipofectamine RNAiMax mixed with 20 pmol (ThermoFisher) or 100 pmol (GE Dharmacon) siRNAs in OptiMEM (31985070, ThermoFisher)) for 24-72 hr before cell collection and sample analysis.
ASO transfection
Control ASO and ASOs targeting unique exons of PCAT19-long were purchased from QIAGEN. ASO target sequences are listed in Table S2 . Lipofectamine RNAiMax reagent was used for transient transfection according to manufacturer's instructions. Briefly, 3 3 10 5 cells were plated in 6-well plates overnight and incubated the next day with the transfection mixture (9 mL Lipofectamine RNAiMax mixed with 100 pmol ASO in OptiMEM (31985070, ThermoFisher)) for at least 24 hr before cell collection and RNA extraction or downstream functional analysis. Plasmid overexpression PCAT19-long was amplified using PCR with NEBNext High-Fidelity 2x PCR Master Mix (M0541S, New England Biolabs), and subsequently cloned into pCDH-CMV-MCS-EF1-Puro overexpression plasmid (CD510B-1, System Biosciences) using restriction enzymes NheI (R3131S, New England Biolabs) and EcoRI (R3101S, New England Biolabs). Plasmids were amplified in OneShot Stbl3 chemically competent E. Coli (C737303, ThermoFisher) with Ampicillin (AB0028, Bio Basic Canada Inc) selection. Empty or overexpression plasmids were transiently transfected using Lipofectamine 3000 (L3000015, ThermoFisher) according to manufacturer's instructions. Briefly, 3 3 10 5 cells were plated in 6-well plates overnight and subsequently incubated with the transfection mixture (5.6 mL Lipofectamine 3000 mixed with 1 mg of plasmid and 2 mL P3000 reagent) for 48 hr before cell collection and RNA extraction or downstream functional analysis.
Lentiviral viral transduction
shRNA transduction shRNA sequences were designed using GPP Web Portal (Broad institute; https://portals.broadinstitute.org/gpp/public/seq/search) and ordered from ThermoFisher (Table S2 ). Sequences were cloned into pLKO.1 vector (10878, Addgene; a gift from David Root) using restriction enzymes AgeI (R3553S, New England Biolabs) and EcoRI (R3101S, New England Biolabs). Viral particles were produced and used to infect cells as previously described (Guo et al., 2016) . Briefly, individual shRNA vectors were co-transfected with psPAX2 and pMD2G vectors (12259 and 12260, Addgene; a gift from Didier Trono) into 293FT cells. Supernatant collected at 48 hr post-transfection were used to transduce V16A and 22Rv1 cells seeded in 6-well plates. 24 hr post-infection, cells were selected using 3 mg/ml puromycin (A11138-03, ThermoFisher).
CRISPRi assay
A stable V16A CRISPRi cell line was generated using the Lenti-dCas9-KRAB-blast plasmid (89567, Addgene; a gift from Gary Hon). In brief, lentiviral particles were generated in 293FT cells using the pMDG.2 and psPAX2 packaging plasmids (12259 and 12260, Addgene; a gift from Didier Trono). The V16A cell line was transduced for 24 hr and selected with 10 mg/ml blasticidin (450-190-WL, Wisent) for 5 days. CRISPRi sgRNAs targeting the PCAT19-short and -long promoter were designed using GPP Web Portal (Broad institute; https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design) and sgTiler (Ahmed and He, 2017), and ordered from ThermoFisher (Table S2 ). Sequences were subsequently cloned into lentiGuide-Puro plasmid (52963, Addgene; a gift from Feng Zhang) using restriction enzyme BsmBI (R0580S, New England Biolabs). Lentiviral particles were generated and stable CRISPRi V16A cells were transduced as mentioned above, and selected with 3 mg/ml puromycin (A11138-03, ThermoFisher) for 48 hr. CRISPRa assay A stable LNCaP CRISPRa cell line was generated using the lentiMPH v2 plasmid (89308, Addgene; a gift from Feng Zhang) as mentioned above. Cells were selected with 400 mg /ml Hygromycin (450-141-XL, Wisent). CRISPRa sgRNAs targeting the PCAT19-short and -long promoters were designed, cloned into lentiSAMv2 plasmid (75112, Addgene; a gift from Feng Zhang) using restriction enzyme BsmBI (R0580S, New England Biolabs), packaged and transduced as mentioned above. Transduced LNCaP CRISPRa cells were selected with 5 mg/ml blasticidin (450-190-WL, Wisent).
Chromatin and RNA Immunoprecipitation
ChIP and RIP assays were performed on prostate cancer cell lines 22Rv1 and V16A, respectively, as previously described (Guo et al., 2016) . Briefly, 1 3 10 7 cells were washed with PBS and fixed with 1% formaldehyde for ChIP and 0.3% formaldehyde for RIP, and quenched with 0.125 M glycine (50046, Sigma-Aldrich). Cells were then collected for nuclear extraction by 10 mL of LB1 buffer (50 mM HEPES-KOH, pH 7.5, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% IGEPAL CA-630 and 0.25% Triton X-100; 10 min at 4 C, pelleted), followed by 10 mL of LB2 buffer (10 mM Tris-HCl, pH 8.0, 200 mM NaCl, 1 mM EDTA and 0.5 mM EGTA; 5 min at 4 C, pelleted), and finally re-suspended in LB3 buffer (10 mM Tris-HCl, pH 8, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% sodium deoxycholate, 0.5% N-lauroylsarcosine and protease inhibitor cocktail (11836170001, Roche)). Nuclear lysates were subsequently sonicated using the Bioruptor sonicator (B01060001, diagenode) until they turned clear. Supernatant was collected and incubated with 6 ug of antibodies (NKX3.1 (sc-15022, Santa Cruz Biotechnology), YY1 (sc-1703, Santa Cruz Biotechnology), H3K4me1 (ab8895, Abcam) and H4Keme3 (ab8580, Abcam) for ChIP; HNRNPAB (SAB1100179, Sigma-Aldrich) for RIP) bounded to magnetic beads (88845 and 88847, ThermoFisher Pierce Magnetic Protein beads A and G) at 4 C overnight. Beads were washed six times with RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% CA-630, 0.5% sodium deoxycholate and protease inhibitor cocktail (11836170001, Roche)) and twice with AMBIC (once for RIP) before elution, reverse cross-linking, and subsequent DNA or RNA extraction. For ChIP-qPCR and RIP-RT-qPCR analysis, relative fold enrichment and percentage of input was calculated using the comparative Ct method normalizing to input sample and negative control primers (ChIP) or input sample alone (RIP) ( Table S2) . Data in bar graphs represent means ± SEM of at least two replicates. Statistical analysis was performed with Student's t test. p value < 0.05 was considered to be statistically significant. For ChIP-seq analysis, 5 ng of ChIPed DNA was subjected to library preparation with the Rubicon ThruPLEX-FD kit. The ChIP-Seq library was sequenced to generate 50 bp single-end reads. The trimmed ChIP-Seq reads were aligned to the human genome NCBI37/HG19 using Bowtie2 version 2.2.1 (Langmead and Salzberg, 2012) using the following command: bowtie2 -q -p 5 bowtie2index input.fastq -S output.sam. We then removed the duplicate reads by the following command in bash: samtools view -bS -q 42 output.sam > output.bam. The resulting bam file was sorted and indexed by samtools sort and samtools index commands. MACS2 version 2.0.10 (Zhang et al., 2008) was then used to perform peak calling in its default parameters with the -SPMR flag on (effective genome size = 2.70e 09 , band width = 300, model fold = [5, 50] , qvalue cutoff = 5.00e -02 , broad region calling = off). Resultant bedgraph files were converted to big wiggle files using the UCSC bedGraphToBigWig tool (Kent et al., 2010) .
Chromosome Conformation Capture (3C) Assay The 3C assay was performed in PCa cell line 22Rv1 as previously described (Guo et al., 2016) . Briefly, 1 3 10 7 cells were fixed with 1% formaldehyde and fractionated for nuclear fraction. Nuclear lysates were digested with 400 U PstI (R3140S, New England Biolabs) overnight at 37 C. Digested chromatin fragments were incubated at 16 C overnight in ligation buffer (750 mL of 10% Triton X-100, 750 mL of 10 3 NEB ligation buffer, 75 mL of 10 mg/ml BSA, 5,925 mL of distilled water and 4,000 U T4 DNA ligase (M0202S, New England Biolabs)). DNA was extracted with phenol-chloroform (15593-049, ThermoFisher) and subjected to PCR and qPCR amplifications using primers listed in Table S2 . As a reference control, BAC clone (RPCI-11-450D10, Empire Genomics) containing human genomic region 19q13.2 was digested with PstI and ligated similarly. qPCR signals from ligated BAC DNA were used to normalize 3C interaction frequency.
RNA Pull-down assays Native RNA pull-down assay 1 3 10 6 V16A cells were collected and lysed with cell lysis buffer (20 mM Tris HCl 7.5 pH, 150 mM NaCl, 1mM EDTA, 0.5% IGEPAL CA-630, protease inhibitor cocktail (11836170001, Roche) and RNase inhibitor (03335402001, Roche)) on ice for 10 min. Cell lysate was precleared with Magnetic beads (65001, ThermoFisher). One volume of Buffer A (150 mM KCl, 25 mM Tris HCl pH7.5, 5 mM EDTA, 0.5% IGEPAL CA-630) supplemented with protease inhibitor cocktail (11836170001, Roche) and RNase inhibitor (03335402001, Roche)) was added to each sample, along with biontinylated DNA probes, and incubated at 4 C for 4 hr with rotation. Antisense DNA probes tiling the first exon of the PCAT19-long isoform were designed using Biosearch Technologies Stellaris FISH Probe Designer, and probes with 3 0 biotinTEG modification were purchased from Sigma-Aldrich (probe sequences are listed in Table  S2) . Magnetic beads were then added to the lysate and incubated at room temperature for an additional 45 min with rotation. Beadsprobe-RNA-protein complexes were collected using DynaMag-15 magnetic strip and washed 5 times with Buffer A. 10% beads were used for RNA isolation with TRIzol (15596026, ThermoFisher) and 90% beads were used for protein elution and downstream analysis. Chromatin isolation by RNA pull-down (ChIRP) assay ChIRP-MS assays were performed as previously described (Chu et al., 2012 (Chu et al., , 2015 . In brief, 1 3 10 7 V16A cells were cross-linked with 3% formaldehyde for 30 min and quenched with 0.125M glycine (50046, Sigma-Aldrich). Cell pellets were washed with PBS and resuspended in lysis buffer (50 mM Tris-HCl pH7.0, 10 mM EDTA and 1% SDS) supplemented with protease inhibitor cocktail (11836170001, Roche) and RNase Inhibitor (03335402001, Roche). Cell lysate was sonicated with the Bioruptor sonicator (B01060001, diagenode) until the lysate turned clear. Input was collected from sonicated samples and used as RNA and protein control at later steps. Cell lysates were hybridized at 37 C for 4 hr with two volumes of hybridization buffer and 200 pmol probes. 100 mL of Streptavidin Magnetic C1 beads (65002, ThermoFisher) were then added to each reaction, and samples with beads were incubated at 37 C for an additional 30 min. For the pull-down, DynaMag-15 magnetic strip was used to capture beads-probe-RNA complexes, which were subjected to five washes with 1 mL wash buffer (2x saline sodium citrate (SSC; 15557-044, ThermoFisher), 0.5% SDS) supplemented with PMSF (78830-5G, Sigma-Aldrich). For each sample, 10% beads were used for RNA isolation and 90% beads were sent for mass spectrometry.
Rapid amplification of cDNA ends (RACE) RACE was performed with RLM-RACE kit (AM1700, ThermoFisher) according to manufacturer's instructions. Briefly, RNA was treated with Calf Intestine Alkaline Phosphatase (CIP) and Tabacco Acid Pyrophosphatase (TAP) to remove the 5 0 cap followed by adaptor ligation. Two rounds of nested PCR were performed with adaptor-specific forward primers and gene-specific reverse primers and 2x Taq Froggamix (FBTAQM, FroggaBio). Primer sequences are listed in Table S2 . Final PCR product was subjected to Sanger sequencing at The Centre for Applied Genomics (SickKids).
Promoter and enhancer luciferase reporter assay The region containing both rs11672691 and rs887391 was selected based on DHS signals. This region was cloned from the genome of prostate cancer cell line 22Rv1, which is heterozygous for both risk SNPs. The non-risk and risk allele fragments were amplified using PCR with NEBNext High-Fidelity 2x PCR Master Mix (M0541S, New England Biolabs), and subsequently cloned into the pGL3-basic vector (E1751, Promega) upstream of the luciferase gene for promoter assay using restriction enzymes NheI (R3131S, New England Biolabs) and KpnI (R3142S, New England Biolabs). For the enhancer assay, the region was cloned upstream of the SV40 promoter in the pGL3-promoter vector (E1761, Promega). 5 3 10 4 cells were plated into 24-well plates and co-transfected the next day with reporter vectors and pRL-TK Renilla Luciferase Control Vector (E2241, Promega) using Lipofectamine 3000 reagent (L3000015, ThermoFisher). Cells were collected using passive lysis buffer (E194A, Promega) after 24 hr and luciferase activity was determined using Dual-Luciferase Reporter Assay System (E1960, Promega). Relative luminescent signals were calculated by normalizing luciferase signals with Renilla signals. Quantification of the most representative biological replicate was shown. Data in bar graphs represent means ± SEM of at least three replicates. Rueden et al., 2017) . Representative images were shown and data in bar graphs represent mean ± SEM of at least five replicates. Scratch-wound migration assay was performed as previously described (Liang et al., 2007) . 1 3 10 5 cells were plated onto 24-well plates and incubated overnight. Cells were scraped with a P200 pipette tip and the same field was imaged after 24 hr. Quantification was calculated as fraction of remaining wound area relative to Day 0. Representative images were shown and data in bar graphs represent mean ± SEM of at least three replicates.
In vitro functional assays
Cell-line derived xenograft study 1 3 10 6 shRNA infected and selected V16A and 22Rv1 cells were re-suspended in matrigel (356231, Corning) and injected subcutaneously into the right flank of NOD-SCID mice. Ten mice were injected per experimental group for statistical significance. Experiments were not blinded. Tumor growth was monitored at least three times per week with calipers for a total of 30 days. Tumors were kept below the maximum allowed size of 1,500 mm 3 under the Princess Margaret Cancer Centre Animal Research Centre (PMCC ARC) SOPs. For the tumor growth curve, mean ± SEM tumor volume was plotted for each experimental group at each indicated time point. Tumor weight on the final day of measurement was also plotted. Tumor metastasis was assessed by qPCR using primers targeting human-specific Alu sequences (Table S2) .
Formaldehyde-assisted isolation of regulatory elements (FAIRE) FAIRE was performed on LNCaP and 22Rv1 cells as described previously (Simon et al., 2012) . Briefly, cells were fixed with 1% formaldehyde and quenched with 0.125M Glycine (50046, Sigma-Aldrich). Input samples were digested with RNase A (10109169001, Roche) and Proteinase K (AM2548, ThermoFisher) before reverse cross-linking at 65 C overnight. Reverse cross-linked input samples and cross-linked FAIRE samples were subjected to three rounds of 1:1 volume Phenyl:chloroform:isoamyl extraction. DNA was precipitated using 0.3M sodium acetate (AM9740, ThermoFisher) and two volumes of 95% ethanol, washed with 80% ethanol and re-suspended in 10 mM Tris-HCl (pH 7.4). Precipitated FAIRE DNA samples were digested with RNase A and Proteinase K before reverse cross-linking at 65 C overnight. Primers used for qPCR analysis are listed in Table S2 . Data in bar graphs represent means ± SEM of at least two replicates.
RT-qPCR and cell fractionation Total RNA was extracted using the RNAeasy mini Kit (74106, QIAGEN) according to manufacturer's instructions. Briefly, cells were lysed with TRIzol (15596026, ThermoFisher) and applied to the spin columns. RNA is eluted after on-column DNase digestion and buffer wash. Reverse transcription to cDNA was performed using the High-capacity cDNA reverse transcription kit (4368814, ThermoFisher). RT-qPCR was performed using PowerUp SYBR Green Master Mix (A25742, ThermoFisher) and StepOnePlus Real-Time PCR System (4376600, Thermofisher). Results were analyzed using the comparative Ct method normalizing to a control sample and housekeeping primers (Table S2) . Cell fractionation was performed using the PARIS kit (AM1921, ThermoFisher) according to manufacturer's instructions, followed by RT-qPCR of nuclear and cytoplasmic fractions. Briefly, approximately 1 3 10 6 cells were first lysed with Cell Fractionation Buffer on ice and spun down. Supernatants were kept for the cytoplasmic fraction. Pellets were further lysed with Cell Disruption Buffer on ice for the nuclear fraction. RNA from both fractions were extracted through filter columns supplied.
Western blotting and silver staining Protein samples from pull-down and siRNA-mediated knockdown assays were diluted with 4x Laemmli sample buffer (#161-0747, Biorad) and boiled for 30 and 10 min, respectively. Proteins were resolved in mini-PROTEAN TGX Gels (#456-9036, Biorad) and transferred onto PVDF membranes. Membranes were blocked with 5% skim milk at room temperature, and then incubated with the appropriate primary antibodies at 4 C overnight and secondary antibodies at room temperature for 1 hr (See Key Resources Table) .
Primary antibodies used for western blot were HNRNPAB (sc-376411, Santa Cruz) and Vinculin (13901, CST). Secondary antibodies used were anti-mouse (7076S, CST) and anti-rabbit (7074S, CST). Antibody-bound proteins were visualized by ECL substrate (34096, ThermoFisher). Silver staining was performed using the Pierce Silver Stain Kit (24612, ThermoFisher) following manufacturer's instructions. Briefly, gels were fixed with 30% ethanol:10% acetic acid solution for 30 min, and subsequently sensitized, stained, and developed using the appropriate solutions from the kit. Developing reaction was stopped using 5% acetic acid solution.
Data acquisition
The VCaP PolII ChIP-seq signals were obtained from GEO: GSE14097 (Yu et al., 2010 et al., 2005) and Mayo clinic (Larson et al., 2015) . SNP genotype data were obtained from CPC-GENE (EGA: EGAS00001000900) (Fraser et al., 2017 ), TCGA (Cancer Genome Atlas Research Network, 2015 and Mayo clinic (Larson et al., 2015) . The haplotype phased variant calls data for the EUR population were downloaded from the 1000 Genomes Project (Phase III, release 2013/05/ 02) (Auton et al., 2015) .
Survival analysis
Analysis was performed on CPC-GENE (n = 127) (Fraser et al., 2017) and TCGA (n = 333) (Cancer Genome Atlas Research Network, 2015) cohorts. Clinical survival endpoint for CPC-GENE is biochemical recurrence as defined by PSA level, and for TCGA is diseasefree survival. Samples with missing genotype, expression or patient survival data were excluded from the survival analyses. Specifically, patients were segregated based on SNP genotype, median expression of PCAT19 isoforms, all PCAT19-long upregulated genes, and PCAT19-long activity score. The survival analyses were performed and visualized as Kaplan-Meier plots using the functions ''survfit'' and ''ggsurvplot'' in the R packages ''Survival'' version 2.40 (Therneau and Grambsch, 2000; Therneau, 2015) and ''Survminer'' version 0.4.2 (Kassambara and Kosinski, 2018) , respectively, in R version 3.3.3. Survival models were first generated using the function Surv with ''time to event'' and ''event status'' from clinical cohorts as the input. Then the SNP genotype or gene expression was fitted to the models using the function survfit. The fitted models were visualization using the function ggsurvplot with the following parameters: pval = TRUE and risk.table = TRUE. Statistical significance was calculated using the log-rank test.
RNA-seq and differential expression analysis V16A cells were transfected by control siRNA or siRNAs targeting PCAT19-long or HNRNPAB for 48 hr. RNAs were extracted using the RNAeasy mini Kit (74106, QIAGEN) according to manufacturer's instructions. Briefly, cells were lysed with TRIzol (15596026, ThermoFisher) and applied to the spin columns. RNA is eluted after on-column DNase digestion and buffer wash. RNA-seq libraries were prepared using the TruSeq Stranded mRNA Library Preparation Kit (RS-122-2101, Illumina) following the Low Sample (LS) protocol. Sequencing was performed at the Princess Margaret Genomic Centre. The reads were aligned against the human genome assembly Hg19 using TopHat2 version 2.1.0 (Kim et al., 2013) with default settings (annotation GTF file for -G and bowtie2 index file). We then retained only the top quality mapped reads by the following command: samtools view -bq 50 input.bam > output.bam. The read counts were quantitated against gene annotation GENCODE v19 (for siPCAT19) or Refgene (for siHNRNPAB) using the function featureCounts in the R package ''Rsubread'' version 1.24.2 (Liao et al., 2014) , specifically using the following parameters: annot.ext = annotation file and isGTFAnnotationFile = TRUE. Lowly expressed genes (< 1 cumulative read count across samples) were removed. Differential expression analysis was performed from read counts using DESeq2 version 1.14.1 package in R (Love et al., 2014) with default parameters. A threshold of 1.5-fold change and < 0.1 FDR was used to obtain a final list of differentially expressed genes. GO enrichment analysis was performed on PCAT19-long upregulated genes using DAVID 6.7 (Huang et al., 2009a; 2009b) . Gene Set Enrichment Analysis (Subramanian et al., 2005) was performed using the R package ''Clusterprofiler'' version 3.2.14 (Yu et al., 2012) using the functions GSEA (verbose = TRUE and maxGSSize = 500) and gseaplot with the default parameters. Genes were ranked based on expression fold change (high to low) between siCtrl and siHNRNPAB, and the 113 PCAT19-long upregulated genes were used as a custom gene-set.
Expression and eQTL analysis
We performed the expression quantitative trait loci analysis using the R package ''MatrixEQTL'' version 2.2 (Shabalin, 2012). For the TCGA cohort, all RNA-seq FASTQ files were downloaded from the TCGA data hub. The RNA-seq data were mapped to human genome assembly Hg19 using TopHat2 version 2.1.0 (Kim et al., 2013) and the gene expression was quantitated using Cufflinks version 2.1.1 (Trapnell et al., 2010) against the MiTranscriptome gene annotation (Iyer et al., 2015) . The raw Affy 6.0 genotyping data for the TCGA cohort in CEL format were also obtained from their data hub. The data were processed using the program birdseed from the birdsuite set of tools (Korn et al., 2008) . We performed the expression quantitative trait loci analysis by fitting a linear regression model between the expression and the genotype data using the R package ''MatrixEQTL'' version 2.2 (Shabalin, 2012). We used the function Matrix_eQTL_main with its default parameters (pvOutputThreshold = 0.05, cisDist = 5e 5 ). Any variant with minor allele frequency of 0.05 were removed. The cis-eQTL was defined as variant-gene association within 500 kbp. The p values were corrected for multiple testing using Bonferroni method.
Intercellular functional correlation
The DHS signal data for the SNP region and the PCAT19-long promoter region for 73 cell lines were downloaded from the UCSC ENCODE download page (http://genome.ucsc.edu/ENCODE/downloads.html) (ENCODE Project Consortium, 2012) in bigwig format. The PCAT19-long promoter region was defined as a region of 500 bp upstream and downstream of the transcription start site as annotated in MiTranscriptome annotation (hg19 chr19:42006618-42007618). The SNP region was defined similarly as 500bp up and downstream around the SNP position (hg19 chr19: 41, 985, 986, 088) . The analysis was performed as previously described (Guo et al., 2016) . Briefly, the Pearson's correlation coefficient (PCC) between the average DHS signal intensity of this pair of regions was computed using the function cor.test in R (version 3.3.0) in its default parameters (alternative = ''two.sided,'' method = ''pearson''). The principle of intercellular functional correlation was first described by Thurman et al. (2012) . The principle describes that any two genomic regions with highly correlated DNase I signals across different cell lines are likely to be physically associated. The 73 cell lines were grouped into 32 clusters as described in the original article (Thurman et al., 2012) Shin et al., 2006) with the following parameters: gdat = matrix generated by PLINK, genetic.distances = genomic coordinates from the map file, SNP.name = rsIDs from the map file, color = heat.colors(20).
Motif analysis
The effect of rs11672691 and rs887391 on transcription factor binding motifs was analyzed using HaploReg v4.1 (http://archive. broadinstitute.org/mammals/haploreg/haploreg.php) (Ward and Kellis, 2012) in its default settings (LD r 2 threshold of 0.8, EUR population, ChromHMM (Core 15-state model) as the source of epigenomes). The SNPs rs11672691 and rs887391 and their flanking sequences overlap with NKX3.1 and YY1 motifs, respectively.
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analyses were performed using RStudio (version 1.0.136) with R version 3.3.3 and GraphPad Prism 6 software. Data are shown as mean ± SEM ''n'' represents the number of technical replicates of the representative biological replicate unless otherwise mentioned. Details of the statistical analysis for each experiment can be found in the relevant figure legends. All statistical analyses were calculated using unpaired two-tailed Student's t test unless otherwise mentioned. Statistical analyses for gene expression in clinical cohorts with more than two groups were calculated using one-way ANOVA. Statistical analyses for all Kaplan Meier survival curves were calculated using log-rank test. Asterisks define the significance level (* p % 0.05; ** p % 0.01; *** p % 0.001). All Image quantifications for migration and invasion studies were performed using ImageJ2 version 10.2 (Rueden et al., 2017) . Number of cells in Boyden chamber assay was quantified using the ''analyze particles'' function. Remaining wound area in the scratch-wound assay was quantified as rectangular area unoccupied by cells.
DATA AND SOFTWARE AVAILABILITY
The accession number for the PCAT19 and HNRNPAB siRNA RNA-seq reported in this paper is GEO: GSE106774. The accession number for the 22Rv1 H3K4me1 and H3K4me3 ChIP-seq reported in this paper is GEO: GSE112120.
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